Table 1.
Clinical characteristics of the discovery and validation cohorts
| Phenotype | Factor | All | Discovery cohort | Validation cohort |
|---|---|---|---|---|
| MCI-C | Number of subjects | 83 | 41 | 42 |
| Age ± SD | 75.22 ± 6.22 | 75.10 ± 5.64 | 75.33 ± 6.81 | |
| Percentage of male (# patients) | 29 (24) | 41 (17) | 17 (7) | |
| Number of APOE4 alleles (# patients) | 0 (46), 1 (29), 2 (8) | 0 (25), 1 (13), 2 (3) | 0 (21), 1 (16), 2 (5) | |
| Follow-up, mean ± SD (days) | 927.18 ± 535.03 | 1014.07 ± 593.22 | 842.36 ± 462.90 | |
| MCI-NC | Number of subjects | 114 | 57 | 57 |
| Age ± SD | 75.56 ± 6.39 | 75.42 ± 5.75 | 75.70 ± 7.02 | |
| Percentage of male (# patients) | 43 (49) | 44 (25) | 42 (24) | |
| Number of APOE4 alleles (# patients) | 0 (80), 1 (32), 2 (2) | 0 (40), 1 (15), 2 (2) | 0 (40), 1 (17), 2 (0) | |
| Follow-up, mean ± SD (days) | 1002.23 ± 564.49 | 939.70 ± 554.31 | 1064.75 ± 572.52 | |
| Total subjects | 197 | 98 | 99 |
MCI-C mild cognitive impairment converters (to Alzheimer’s disease), MCI-NC mild cognitive impairment non-converters, SD standard deviation